Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02850016 · ClinicalTrials.gov registry record · Phase 2

Romidepsin Plus 3BNC117 Phase 2a Study

A Phase 2 study of Human Immunodeficiency Virus (HIV), sponsored by Rockefeller University.

Completed
Registry status
Phase 2
Development phase
48
Enrollment target
3
Study locations

NCT02850016 is a Phase 2 study of Human Immunodeficiency Virus (HIV) that has completed, run by Rockefeller University. The registered enrollment target is 48 participants, below the 506-participant average among 18 other Human Immunodeficiency Virus (HIV) trials with a reported enrollment target (91% lower). The trial reports 3 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02850016, a Phase 2 study of Human Immunodeficiency Virus (HIV), has completed, sponsored by Rockefeller University.

COMPLETED
Registry status
Phase 2
Development phase
48 participants
Enrollment target
3
Study locations

Study Summary

The aim of this protocol is to evaluate the effects of romidepsin plus 3BNC117 or romidepsin alone on delaying or preventing viral rebound in ART-treated HIV-1-infected individuals during an analytical interruption of ART.

Conditions Studied

Human Immunodeficiency Virus (HIV)

Interventions

  • DRUG Romidepsin
  • DRUG 3BNC117

Study Locations (3)

Other

  • Aarhus University Hospital - Aarhus
  • University of Cologne - Cologne

New York

  • The Rockefeller University - New York

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2017-01-06
Est. Completion 2020-12-31
Phase Phase 2

Sponsor

Rockefeller University

117 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02850016

The ClinicalTrials.gov registry entry for NCT02850016 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 506-participant average among 18 other Human Immunodeficiency Virus (HIV) trials with a reported enrollment target (91% lower). The listed sponsor is Rockefeller University, which has 117 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Human Immunodeficiency Virus (HIV) appearing as the primary indexed condition, and to 2 interventions - of which Romidepsin is the first listed.

NCT02850016 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Other, New York.

Frequently Asked Questions

What is clinical trial NCT02850016 about?

NCT02850016 is a clinical study titled "Romidepsin Plus 3BNC117 Phase 2a Study". The aim of this protocol is to evaluate the effects of romidepsin plus 3BNC117 or romidepsin alone on delaying or preventing viral rebound in ART-treated HIV-1-infected individuals during an analytical interruption of ART.

What is the current status of trial NCT02850016?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2017-01-06. Estimated completion is 2020-12-31.

What conditions does trial NCT02850016 study?

This clinical trial studies the following conditions: Human Immunodeficiency Virus (HIV).

What interventions are being tested in trial NCT02850016?

The interventions under investigation include: Romidepsin (DRUG), 3BNC117 (DRUG).

Who is sponsoring clinical trial NCT02850016?

This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02850016 being conducted?

This trial has 3 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Human Immunodeficiency Virus (HIV)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Human Immunodeficiency Virus (HIV)

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.